



Improving Frailty Assessment in Myelofibrosis Patients in Haematology Outpatients

Lisa Lefley BSc (Hons)
Haematology Nurse Specialist


The Problem

Standard practice does not include a frailty assessment for Myelofibrosis patients who attend the outpatient clinic. This has a negative impact on patient outcome and experience.


Smart Aim

To complete a frailty score assessment for 10% of Myelofibrosis patients over a five week period who come to clinic.

Driver Diagram




Stake Holders
MPN CNS Nursing team
MPN Consultants and Doctors
GPs and Community Services



PDSA Cycle 1



In order to achieve our aim we mapped out the patient pathway to see where the frailty assessment could be implemented and sustained (shown in red).



Process Measures


- Appointments – 6 extra appointments were required above what would have normally occurred. This is a result of frailty score being assessed over the telephone in the first instance and then requiring a further face to face appointment to measure for accuracy.
- Scores >4 then required a further follow up appointment at 12 weeks.
- Time – 1.5 hours extra were required to make the necessary referrals to community support services.

Balancing Measures

Time – Extra time required in new patient appointment to conduct a Frailty assessment and to ensure that they have a baseline BMI recorded.

Outcome Measures

TOTAL % OF MF PATIENTS WITH A FRAILTY SCORE



Next Steps

- Role out frailty assessment for the wider MPN cohort.
- We have implemented that all patients that attend clinic face to face have their weight recorded on a monthly basis.
- Frailty is not synonymous with age and many of our patients are younger than 65years, therefore we are continuing our search for a frailty scoring tool that can be used on these younger patients.
- Patient satisfaction surveys are planned to be rolled out to capture their views as a follow up to this project.
- A further PDSA cycle is planned to roll out the frailty score assessment for our Myelodysplastic and AML patients.